Journal
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM
Volume 5, Issue 2, Pages 34-38Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2042018814543483
Keywords
dipeptidyl peptidase-4 inhibitors; glucagon-like peptide-1; glycemic control; incretin; liraglutide; metabolic syndrome; obesity; psoriasis; type 2 diabetes
Categories
Ask authors/readers for more resources
Glucagon-like peptide-1 (GLP-1) agonists are a class of drugs used for the treatment of type 2 diabetes mellitus. GLP-1 is released in response to meal intake; these classes of drugs enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic effects following their release into the circulation from the gut. Psoriasis is a chronic skin condition affecting approximately 2% of the Western population. It is considered to be an autoimmune disease that involves the Th1 pathway and is associated with metabolic syndrome and its components, such as obesity, diabetes, and hypertension. We have reviewed reports in the literature that indicate a beneficial anti-inflammatory effect of GLP-1 in patients with diabetes or who have insulin resistance and psoriasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available